Fibrocor Therapeutics formed to develop fibrotic disease treatments

17 January 2017
2019_biotech_test_vial_discovery_big

German biotech firm Evotec (EVT: Xetra) and MaRS Innovation today announced the launch of Fibrocor Therapeutics, a Toronto, Canada-based company focused on developing first-in-class therapeutics targeting fibrotic diseases.

The company was launched with C$2.8 million (~$2.1 million) financing, which includes cash from MaRS Innovation, the commercialization agent for 15 of Ontario's leading academic institutions. Evotec will provide all drug discovery activities and will also receive an equity stake.

Fibrocor takes a new approach to understanding and treating fibrosis, bringing together clinical expertise and access to disease tissue with high-throughput molecular analysis infrastructure and expertise in clinically-predictive animal models of fibrosis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology